June 11, 2020
COVID-19 Vaccine Developers Search for Antibodies That ‘First Do No Harm’ | Consensus summary report for CEPI/BC March 12–13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines
COVID-19 Vaccine Developers Search for Antibodies That ‘First Do No Harm’ | Consensus summary report for CEPI/BC March 12–13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 | Predicting infectious SARS-CoV-2 from diagnostic samples | Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis
Developing Covid-19 Vaccines at Pandemic Speed | Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial | Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis
Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19 | Cigarette smoke exposure and inflammatory signaling increase the expression of the SARS-CoV-2 receptor ACE2 in the respiratory tract
An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study | Preventing a Parallel Pandemic — A National Strategy to Protect Clinicians’ Well-Being | Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
Arterial thromboembolic complications in COVID-19 in low risk patients despite prophylaxis | Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State | Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19
Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young | Hyperinflammatory shock in children during COVID-19 pandemic | Interpreting Diagnostic Tests for SARS-CoV-2 | The Ecology of Being Human by Dickson Despommier
By Dickson Despommier —
Since their establishment some 11,000 years ago, as of 2020, cities with populations greater than one hundred thousand have evolved and grown to accommodate some 60% of us (that’s 4.4 billion individuals). The trend is clear. In another 50 years it is estimated that over 80% of the human population will live in cities.
ACE inhibitors and ARBS not linked to COVID-19 infection or severity | Effective treatment of severe COVID-19 patients with tocilizumab | Insight into FDA’s Revised Policy on Antibody Tests: Prioritizing Access and Accuracy
Pulmonary Embolism and Increased Levels of d-Dimer in Patients with Coronavirus Disease | Adaptive COVID-19 Treatment Trial “ACTT” (NIAID) | SIMPLE I Trial results (Gilead) | Remdesivir in Chinese adults with severe COVID-19
A comprehensive educational resource on all aspects of parasitic diseases and their impact on humanity around the globe.
Help bring the latest medical and basic biological information pertaining to diseases caused by eukaryotic parasites to every practicing physician and medical student within the United States.